At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
LY3023414 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating LY3023414, Enzalutamide, and 1 other intervention for Prostate Cancer Metastatic. Completed, enrolled 142 participants across 36 sites.
Detailed Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer Metastatic
CountriesUnited States
CollaboratorsSarah Cannon
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartApr 2015
Primary CompletionSep 2018
Study CompletionApr 2020
TodayJul 2026
First PostedApr 2, 2015
Enrollment StartApr 29, 2015
Primary CompletionSep 26, 2018
Study CompletionApr 16, 2020
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.3 years ago
Interventions
LY3023414drug
Administered orally
Enzalutamidedrug
Administered orally
Placebodrug
Administered orally